一种用于检测早期肝细胞癌的新型血液甲基化DNA与蛋白标志物组合
多中心病例对照研究纳入135例肝细胞癌患者和302例年龄匹配的肝病对照,评估由3个甲基化DNA标志物(HOXA1、EMX1、TSPYL5)、B3GALT6及2个蛋白标志物(AFP、AFP-L3)组成的血液标志物组合,其在90%特异性下对早期肝细胞癌的灵敏度为71%(95%CI:60-81%),高于GALAD评分(41%,95%CI:30-53%)和AFP≥7.32 ng/mL(45%,95%CI:33-57%)。
要点
- 多靶点血液标志物组合对早期肝细胞癌灵敏度71%(95%CI:60-81%),特异性90%。
- 该组合灵敏度高于GALAD评分(41%)和AFP≥7.32 ng/mL(45%)。
- 检测任何分期肝细胞癌的AUC为0.92,高于GALAD评分0.87和单独AFP 0.81。
核心结论
- 研究开发了一种新型血液标志物组合,对早期肝细胞癌显示出高灵敏度,数据支持液体活检检测早期肝细胞癌可能使高危患者临床获益。
研究设计与样本
- 多中心病例对照研究,纳入135例肝细胞癌患者和302例年龄匹配的、有基础肝病但无肝细胞癌的对照。
- 检测10种既往报道的肝细胞癌相关甲基化DNA标志物、甲基化B3GALT6(参考DNA标志物)和3种候选蛋白(包括AFP),并用逻辑回归算法预测肝细胞癌。
主要发现
- 在90%特异性下,由3种甲基化DNA标志物(HOXA1、EMX1、TSPYL5)、B3GALT6和2种蛋白标志物(AFP、AFP-L3)组成的多靶点组合对早期肝细胞癌的灵敏度为71%(95%CI:60-81%),高于GALAD评分的41%(95%CI:30-53%)和AFP≥7.32 ng/mL的45%(95%CI:33-57%)。
- 该多靶点组合检测任何分期肝细胞癌的AUC为0.92,GALAD评分为0.87,单独AFP为0.81。
- 该组合在基于肝病病因、肝硬化存在与否或性别划分的重要亚组中表现相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) can be treated effectively if detected at an early stage. Recommended surveillance strategies for at-risk patients include ultrasound with or without α-fetoprotein (AFP), but their sensitivity is suboptimal. We sought to develop a novel, blood-based biomarker panel with improved sensitivity for early-stage HCC detection. METHODS: In a multicenter, case-control study, we collected blood specimens from patients with HCC and age-matched controls with underlying liver disease but without HCC. Ten previously reported methylated DNA markers (MDMs) associated with HCC, methylated B3GALT6 (reference DNA marker), and 3 candidate proteins, including AFP, were assayed and analyzed by a logistic regression algorithm to predict HCC cases. The accuracy of the multi-target HCC panel was compared with that of other blood-based biomarkers for HCC detection. RESULTS: The study included 135 HCC cases and 302 controls. We identified a multi-target HCC panel of 3 MDMs (HOXA1, EMX1, and TSPYL5), B3GALT6 and 2 protein markers (AFP and AFP-L3) with a higher sensitivity (71%, 95% CI: 60-81%) at 90% specificity for early-stage HCC than the GALAD score (41%, 95% CI: 30-53%) or AFP ≥7.32 ng/mL (45%, 95% CI: 33-57%). The AUC for the multi-target HCC panel for detecting any stage HCC was 0.92 compared with 0.87 for the GALAD score and 0.81 for AFP alone. The panel performed equally well in important subgroups based on liver disease etiology, presence of cirrhosis, or sex. CONCLUSIONS: We developed a novel, blood-based biomarker panel that demonstrates high sensitivity for early-stage HCC. These data support the potential for liquid biopsy detection of early-stage HCC to clinically benefit at-risk patients. This study was registered on ClinicalTrials.gov (NCT03628651).
引用
- Chalasani NP, Ramasubramanian TS, Bhattacharya A, et al. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020. PMID: 32889146. doi:10.1016/j.cgh.2020.08.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。